Compositions and methods for identifying and targeting cancer cells of alimentary canal origin

• US 7,854,933 B2
• Filed: 06/14/2004
• Issued: 12/21/2010
• Est. Priority Date: 03/27/2000
• Status: Expired due to Term

• Current Assignee: Thomas Jefferson University (Main Line Health System)
• Original Assignee: Thmoas Jefferson University
• Inventors: Waldman, Scott A., Park, Jason, Schulz, Stephanie
• Primary Examiner(s): Goddard; Laura B
• Application Number:
  US10/866,951
• Publication Number:
  US 20040224355A1
• Time in Patent Office: 2,381 Days
• Field of Search: None
• US Class Current: 424/181.1
• CPC Class Codes: A61K 31/7034 attached to a carbocyclic compound, e.g. phloridzin
• CPC Class Codes: A61K 31/7048 having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin , digitoxin or digoxin
• CPC Class Codes: A61K 39/001102 Receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: A61K 47/6871 the antibody targeting an enzyme
• CPC Class Codes: A61K 51/1075 the antibody being against an enzyme
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: C07K 16/3046 Stomach, Intestines
• CPC Class Codes: C07K 16/40 against enzymes
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/158 Expression markers
• CPC Class Codes: G01N 2333/988 Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
• CPC Class Codes: G01N 33/57407 Specifically defined cancers
• CPC Class Codes: G01N 33/57419 of colon
• CPC Class Codes: G01N 33/57446 of stomach or intestine

Abstract

Screening and diagnostic reagents, kits and methods for primary and/or metastatic stomach or esophageal cancer are disclosed. Compositions for and methods of imaging and treating primary and/or metastatic stomach or esophageal cancer are disclosed. Vaccines compositions and methods of for treating and preventing primary and/or metastatic stomach or esophageal cancer are disclosed.

Claims

1. A method of treating an individual suspected of suffering from primary and/or metastatic esophageal cancer comprising the steps of administering to said individual a therapeutically effective amount of a composition comprising:

i) a guanylyl cyclase C ligand; and

ii) a therapeutic agent,

wherein the guanylyl cyclase C ligand is conjugated to the therapeutic agent, and wherein the guanylyl cyclase C ligand is an antibody which binds to SEQ ID NO;

2.

2. The method of claim 1 wherein said therapeutic agent is selected from the group consisting of:

methotrexate, doxorubicin, daunorubicin, cytosinarabinoside, etoposide, 5-4 fluorouracil, melphalan, chlorambucil, cis-platinum, vindesine, mitomycin, bleomycin, purothionin, macromomycin, 1,4-benzoquinone derivatives, trenimon, ricin, ricin A chain Pseudomonas exotoxin, diphtheria toxin, Clostridium perfringens phospholipase C, bovine pancreatic ribonuclease, pokeweed antiviral protein, abrin, abrin A chain, cobra venom factor, gelonin, saporin, moceccin, viscumin, vokensin, alkaline phosphatase, nitroimidazole, metronidazole, misonidazole, ⁴⁷Sc, ⁶⁷Cu, ⁹⁰Y, ¹⁰⁹Pd, ¹²³I, ¹³¹I, ¹⁸⁶Re, ¹⁸⁸Re, ¹⁹⁹Au, ²¹¹At, ²¹²Pb, ¹²¹B, ³²P and ³³P, ⁷¹Ge, ⁷⁷As, ¹⁰³Pb, ¹⁰⁵Rh, ¹¹¹Ag, ¹¹⁹Sb, ¹²¹Sn, ¹³¹Cs, ¹⁴³Pr, ¹⁶¹Tb, ¹⁷⁷Lu, ¹⁹¹Os, ¹⁹³MPt, ¹⁹⁷Hg, ⁴³K, ⁵²Fe, ⁵⁷CO, ⁶⁷Cu, ⁶⁸Ga, ⁷⁷Br, ⁸¹Rb/^81MKr, ^87MSr, ^99MTc, ¹¹¹In, ^113MIn, ¹²⁵I, ¹²⁷Cs, ¹²⁹Cs, ¹³²I, ¹⁹⁷Hg, ²⁰³Pb and ²⁰⁶Bi.

3. The method of claim 1 wherein the antibody is a monoclonal antibody.

4. The method of claim 1 wherein the antibody is a FAb or a F(Ab)₂.

5. The method of claim 1 wherein said therapeutic agent is selected from the group consisting of:

chemotherapeutics, toxins and radiosensitizing agents.

6. The method of claim 1 wherein said composition is administered to said individual by injection.

7. The method of claim 1 wherein said composition is administered to said individual intravenously.

8. The method of claim 1 wherein said individual has metastatic esophageal cancer.

9. The method of claim 1 wherein said therapeutic agent is selected from the group consisting of:

compounds that cause cell death, compounds that inhibit cell division, and compounds that induce cell differentiation and radiosensitizing agents.